Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase II Trial of Neoadjuvant Erlotinib (Tarceva®) Followed by Surgery for Selected Patients With Stage IIIA, N2-positive Non-Small Cell Lung Cancer

NCT01130753 is registered in ClinicalTrials.gov with Samsung Medical Center as lead sponsor.

NCT NCT01130753
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT01130753 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase II Trial of Neoadjuvant Erlotinib (Tarceva®) Followed by Surgery for Selected Patients With Stage IIIA, N2-positive Non-Small Cell Lung Cancer
Lead sponsor
Samsung Medical Center
Phase
Phase 2
Overall status
Completed
Start date
January 31, 2007
Completion date
December 31, 2012
Enrollment
43 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

erlotinib, lung neoplasms, neoadjuvant therapy